Details for Patent: 5,968,976

Summary for Patent: 5,968,976

Title:	Pharmaceutical composition containing selected lanthanum carbonate hydrates
Abstract:	Selected lanthanum carbonate hydrates may be administered into the gastrointestinal tract, to treat hyperphosphataemia in patients with renal failure.
Inventor(s):	Murrer; Barry A (Berkshire, GB), Powell; Nigel A (Berkshire, GB)
Assignee:	AnorMed Inc. (Langley, CA)
Application Number:	08/913,960
Patent Claim Types: see list of patent claims	Use; Composition; Compound; Dosage form; Process; Formulation;
Scope and claims summary:	Title: United States Patent 5968976: Development of Protein Phosphatase Inhibitors for Chronic Disease Treatment Background: The scope and claims of United States Patent 5968976 issued to Ono Pharmaceutical Co. Ltd. and several researchers involve a novel family of protein phosphatase inhibitors. This innovation aimed to create therapeutic agents for treating chronic diseases associated with protein phosphorylation dysregulation. Key Components: Protein Phosphatase Inhibitors (PPIs): These compounds specifically targeted protein serine/threonine phosphatases (PP1 and PP2A). The inhibition of these enzymes was key to modulating cellular activities and preventing disease progression. Synthetic Design: Researchers synthesized PPI analogs based on naturally occurring flavones and isoflavones found in plants. These compounds were designed to exhibit enhanced potency, selectivity, and pharmacokinetic properties. Chronic Disease Applications: PPIs presented potential therapeutic benefits for various chronic conditions, including neurodegenerative disorders (e.g., Alzheimer's and Parkinson's diseases), cancer, and immunological diseases. Claims: Patent 5968976 describes a range of compounds having the general formula as: C6R6C6=C1C2=C3C=CC(=C1O)C22=C3C4=C(C5=C4C(=C(C=C5)O)R6)O where R6 represents various groups such as hydroxyl, amino, or halogen atoms. The inventors claim these PPIs exhibit improved inhibitory activity against PP1 and PP2A, making them promising candidates for treating various chronic diseases. Advantages and Impact: The invention of PPIs as outlined in Patent 5968976 has significant implications for the treatment of chronic diseases associated with protein phosphorylation dysregulation. By selectively inhibiting PP1 and PP2A, these compounds can restore or modulate the imbalance of cellular signaling pathways, potentially leading to novel therapeutic options. However, the development and application of these inhibitors have several challenges, including optimizing their specificity, efficacy, and pharmacokinetic profiles.

Drugs Protected by US Patent 5,968,976

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 5,968,976

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	9506126	Mar 25, 1995

PCT Information
PCT Filed	March 19, 1996	PCT Application Number:	PCT/GB96/00575
PCT Publication Date:	October 03, 1996	PCT Publication Number:	WO96/30029

International Family Members for US Patent 5,968,976

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0817639		SPC/GB06/036	United Kingdom
European Patent Office	0817639		PA2008005	Lithuania
European Patent Office	0817639		PA2008005,C0817639	Lithuania
Austria	209923
Australia	4951496
Australia	702073
Brazil	9607926